University of California San Francisco
Give to UCSF
A new long-acting HIV treatment could expand options for people who have trouble taking daily pills and whose virus is resistant to some commonly used HIV drugs, according to a new UCSF study. This drug combination could offer an option for people whose virus is resistant to a key drug in the only approved long-acting combination treatment.
UCSF reserachers discover why people with controlled HIV are at much higher risk for diabetes than HIV-negative people.
UCSF researchers presented data that found that the U.S. government’s withdrawal of funding for global HIV programs in January 2025 sharply reduced the number of people entering HIV care across East Africa within weeks.
A new UCSF study looks at the real reasons women with HIV are dying earlier than people without HIV, and finds these leading causes are largely missing from official death records.
UCSF received $824 million from the National Institutes of Health (NIH) in 2025 to drive the discovery, translational, and clinical science that leads to new treatments for disease and advances U.S. leadership in health and science.
UCSF researchers have made strides toward an HIV cure, showing experimental immunotherapy can help control the virus without long-term antiretroviral therapy (ART). In a small study, 7 of 10 participants maintained low HIV levels after stopping medications, reprogramming their immune systems.
Endocrine disruption during pregnancy and genetic drivers of bone disease were among the topics experts from UC San Francisco presented at the annual meeting of the Endocrine Society — ENDO 2025 — in
What do Tinder and the immune system have in common? Both swipe to find the perfect match, but instead of love, the immune system is hunting virus-infected cells. UCSF PhD student Sophia Miliotis explains it all in her clever, three-minute Grad Slam talk – and made history as UCSF’s first-ever winner of the UC-wide competition. Watch it now on UCSF’s YouTube channel.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found.
The quest to defeat HIV/AIDS didn’t just turn a deadly virus into a manageable condition. It transformed science and health care.
A new study on doxy-PEP sheds light on whether people who are regular users become resistance to this treatment, which often serves as a “morning after” pill to prevent sexually transmitted diseases.
Results from a national study led by UCSF informed the first guidelines at the federal level in the U.S. to detect and treat anal cancer precursor lesions in people with HIV to reduce the risk of developing anal cancer.
The COVID-19 pandemic slowed previous gains made in controlling HIV blood levels and worsened health disparities.
A new report from the Lancet Commission on tuberculosis releases recommendations, providing a path forward to turn the tide on this preventable, treatable and curable disease.
Taking daily medication can be a challenge for many, leading to increased viral load over time. Injectable therapies remove that challenge.
A short course of antibiotics, Doxy-PEP, can prevent some STIs after condomless sex.
A sexual health strategy called Doxy-PEP, which involves taking doxycycline after condomless sex, is highly effective in reducing bacterial STIs but is still associated with a limited rise in resistant strains of bacteria.
Three UCSF researchers were named 2022 fellows by the American Association for the Advancement of Science (AAAS), one of the highest honors in science.
Since 1983, Ward 86 has played a revolutionary role in HIV/AIDS treatment, and continues to develop ways to care for people living with HIV.
People who identify as lesbian, gay, bisexual, transgender or non-binary may have a higher risk for stroke at a younger age, and possibly a higher risk for recurrence than those who identify as straight and cisgender.
A significant proportion of bacterial sexually transmitted infections – gonorrhea, chlamydia, or syphilis – were prevented with a dose of doxycycline after unprotected sex, according to preliminary results of a clinical trial.
A groundbreaking national study led by UCSF finds that treating anal cancer precursor lesions reduces cancer risk for people with HIV.
Scientists at UCSF and Makerere University in Kampala, Uganda have developed an intervention that makes use of a portable laboratory testing technology to help HIV providers order, process, and receive HIV viral load results quickly, and shorten the time it takes for patients to get their results.
Individuals with HIV are more than twice as likely to die from sudden cardiac death (SCD) compared to the general population, and more likely to have hearts compromised by fibrosis, a factor that may play a role in increasing their susceptibility to SCD, according to new findings from a UCSF study.
This is one of the first-person perspectives from those who are working on the frontlines to better understand, treat and prevent transmission of HIV and AIDS as well as COVID-19.
